Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | TP53 loss |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04388852 | Phase I | DS-3201b + Ipilimumab | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | Recruiting | USA | 0 |
NCT06136884 | Phase I | AO-252 | A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT02612285 | Phase II | SNX-5422 | Study of SNX-5422 in TP53 Null Cancers | Terminated | USA | 0 |
NCT05691465 | Phase II | lutetium Lu 177 dotatate | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | Recruiting | USA | 0 |
NCT04592237 | Phase II | Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |